Literature DB >> 12800808

A joint model for nonlinear longitudinal data with informative dropout.

Chuanpu Hu1, Mark E Sale.   

Abstract

Subject withdrawal from a study (also called dropout, or right censoring), is common in late phase clinical trials. A number of methods dealing with dropouts have been used in practice, the most common being "last observation carried forward" (LOCF). Many of these methods, including LOCF, can result in biased estimates of the efficacy or potency of the drug, especially in the modeling context. If the likelihood of dropout is correlated to the underlying unobserved data, the dropout is informative and should not be ignored in the modeling process. The topic of informative dropout in the context of longitudinal data has received much attention in the statistical literature, in the setting of linear and generalized linear models. We extend the approach to nonlinear models. The dropout hazard, as well as the longitudinal data, is modeled parametrically. Parameters are estimated by maximizing the approximate joint likelihood as implemented in the software NONMEM. Using data from actual clinical trials, we explore the impact of the dropout model on the ability of the joint model to predict observed longitudinal data patterns.

Mesh:

Year:  2003        PMID: 12800808     DOI: 10.1023/a:1023249510224

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  8 in total

1.  Intention-to-treat: methods for dealing with missing values in clinical trials of progressively deteriorating diseases.

Authors:  K Unnebrink; J Windeler
Journal:  Stat Med       Date:  2001-12-30       Impact factor: 2.373

Review 2.  More efficient clinical trials through use of scientific model-based statistical tests.

Authors:  E Niclas Jonsson; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

Review 3.  Characteristics of indirect pharmacodynamic models and applications to clinical drug responses.

Authors:  A Sharma; W J Jusko
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

4.  Model-based approaches to analysing incomplete longitudinal and failure time data.

Authors:  J W Hogan; N M Laird
Journal:  Stat Med       Date:  1997 Jan 15-Feb 15       Impact factor: 2.373

5.  A joint model for survival and longitudinal data measured with error.

Authors:  M S Wulfsohn; A A Tsiatis
Journal:  Biometrics       Date:  1997-03       Impact factor: 2.571

6.  Population pharmacodynamic model for ketorolac analgesia.

Authors:  J W Mandema; D R Stanski
Journal:  Clin Pharmacol Ther       Date:  1996-12       Impact factor: 6.875

7.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

8.  Coping with missing data in clinical trials: a model-based approach applied to asthma trials.

Authors:  James Carpenter; Stuart Pocock; Carl Johan Lamm
Journal:  Stat Med       Date:  2002-04-30       Impact factor: 2.373

  8 in total
  45 in total

1.  Modelling of pain intensity and informative dropout in a dental pain model after naproxcinod, naproxen and placebo administration.

Authors:  Marcus A Björnsson; Ulrika S H Simonsson
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Joint modeling of multiple longitudinal patient-reported outcomes and survival.

Authors:  Laura A Hatfield; Mark E Boye; Bradley P Carlin
Journal:  J Biopharm Stat       Date:  2011-09       Impact factor: 1.051

Review 3.  Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications.

Authors:  Núria Buil-Bruna; José-María López-Picazo; Salvador Martín-Algarra; Iñaki F Trocóniz
Journal:  Oncologist       Date:  2015-12-14

Review 4.  Modeling and simulation of adherence: approaches and applications in therapeutics.

Authors:  Leslie A Kenna; Line Labbé; Jeffrey S Barrett; Marc Pfister
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

5.  Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

Authors:  Nicholas H G Holford; Phylinda L S Chan; John G Nutt; Karl Kieburtz; Ira Shoulson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-20       Impact factor: 2.745

6.  Tracking motor impairments in the progression of Huntington's disease.

Authors:  Jeffery D Long; Jane S Paulsen; Karen Marder; Ying Zhang; Ji-In Kim; James A Mills
Journal:  Mov Disord       Date:  2013-10-21       Impact factor: 10.338

7.  Establishing the Quantitative Relationship Between Lanreotide Autogel®, Chromogranin A, and Progression-Free Survival in Patients with Nonfunctioning Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Núria Buil-Bruna; Marion Dehez; Amandine Manon; Thi Xuan Quyen Nguyen; Iñaki F Trocóniz
Journal:  AAPS J       Date:  2016-02-23       Impact factor: 4.009

8.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

9.  Performance of nonlinear mixed effects models in the presence of informative dropout.

Authors:  Marcus A Björnsson; Lena E Friberg; Ulrika S H Simonsson
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

10.  Development of a placebo effect model combined with a dropout model for bipolar disorder.

Authors:  Wan Sun; Thomas P Laughren; Hao Zhu; Guenther Hochhaus; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-03-02       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.